NCT04144179View on ClinicalTrials.gov

Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

February 24, 2020

Study Completion Date

February 24, 2020

Conditions
Influenza
Interventions
BIOLOGICAL

Quadrivalent RIV with H3 strain 1

Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular

BIOLOGICAL

Quadrivalent RIV with H3 strain 2

Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular

BIOLOGICAL

Quadrivalent RIV with H3 strain 3

Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular

BIOLOGICAL

Quadrivalent RIV with H3 strain 4

Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular

BIOLOGICAL

Quadrivalent RIV with 2018-2019 NH H3 strain

Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular

Trial Locations (3)

14609

Rochester Clinical Research, Inc. Site Number : 8400001, Rochester

29405

Coastal Carolina Research Center Site Number : 8400003, North Charleston

33024

Research Centers of America Site Number : 8400002, Hollywood

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT04144179 - Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age | Biotech Hunter | Biotech Hunter